Tag Archives: checkpoint targets

January, 2016

  • 4 January

    Baxalta Enters $1.6 Billion Immuno-Oncology Deal with Symphogen

    BANNOCKBURN, Ill. & COPENHAGEN, Denmark–(BUSINESS WIRE)–Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, and Symphogen, a private biopharmaceutical company developing recombinant antibodies and antibody mixtures, today announced a broad strategic immuno-oncology collaboration. Under the terms of the …